Current Treatment and Primary Prophylaxis for Toxoplasmosis
Journal Pharmaceutical Care and Sciences · 10.06.2021 · 1 (2) · 132-135
DOI: 10.33859/jpcs.v2i1.73 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal Pharmaceutical Care and Sciences, online erschienen am 10.06.2021. Verfasst von Reqgi First Trasia. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Background
Toxoplasmosis is still a health problem in the world. This parasite is found cosmopolitan in humans and animals. In Indonesia, the prevalence of positive anti-Toxoplasma gondii substances in humans ranges from 2-63%, but there are still few comprehensive studies on current treatment and prophylaxis to treat it.
Objective
This article will provide an in-depth review of current treatment and primary prophylaxis in toxoplasmosis.
Methods
Searching the latest literature, obtained 10 relevant journals.
Results
Initial therapy Pyrimethamine 200 mg was given for 6 weeks. Maintenance therapy (suppressive, secondary prophylaxis) is given for life if immune reconstitution does not occur. Primary prophylaxis against toxoplasmic encephalitis is given to patients who are seropositive for Toxoplasma.
Conclusion
Initial therapy, maintenance, and primary prophylaxis can be useful to prevent worsening of the prognosis of toxoplasmosis disease.
Zitieren
APA
Trasia, R. F. (2021). Current Treatment and Primary Prophylaxis for Toxoplasmosis. Journal Pharmaceutical Care and Sciences, 1(2), 132-135. https://doi.org/10.33859/jpcs.v2i1.73
Vancouver
Trasia RF. Current Treatment and Primary Prophylaxis for Toxoplasmosis. Journal Pharmaceutical Care and Sciences. 2021;1(2):132-135. doi:10.33859/jpcs.v2i1.73
BibTeX
@article{Trasia2021,
author = {Trasia, Reqgi First},
title = {Current Treatment and Primary Prophylaxis for Toxoplasmosis},
journal = {Journal Pharmaceutical Care and Sciences},
year = {2021},
volume = {1},
number = {2},
pages = {132--135},
doi = {10.33859/jpcs.v2i1.73}
}
EUVIMED